Celgene Corporation Merger With Bristol-Myers Squibb

Celgene Corporation, an immunology pharmaceutical company, merged with Bristol-Myers Squibb (NYSE: BMY), a prescription-manufacturing pharmaceutical company, in a transaction valued at $74 billion.

Morrow Sodali acted as the proxy solicitor for the bidder in this transaction.

Find more information here.